Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Myasthenia gravis stories

Nov 13, 2026

FDA approves injectable nanobody gefurulimab for myasthenia gravis

The FDA granted approval to gefurulimab, a nanobody targeting the complement protein C5, for the treatment of myasthenia gravis, joining other approved C5 inhibitors in the indication.

Nov 13, 2026·2 sources
00

Top claims

  • ▪In September 2026, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended gefurulimab for approval in the European Union
  • ▪The phase III PREVAIL trial randomized 260 adults with anti-AChR antibody-positive generalized myasthenia gravis to evaluate weekly subcutaneous gefurulimab against placebo over 26 weeks
  • ▪The phase III PREVAIL trial met its primary endpoint, demonstrating a statistically significant improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) scale scores versus placebo at week 28 with a treatment difference of -1.6 points

Topics

Neurological disordersEuropean UnionClinical trialsAutoimmune disease treatmentsRandomized controlled trialRisk evaluation & mitigation (REMS)FDA drug approvalDrug safetyDrug Policy, Pricing & Approval

Related entities

United StatesNeisseria meningitidis